Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status

INTRODUCTION: Certain genetic features in chronic lymphocytic leukemia (CLL) are associated with inferior outcomes after chemoimmunotherapy (CIT). This retrospective study evaluated treatment patterns and clinical outcomes of patients with CLL, stratified into high-risk and non-high-risk groups, who...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qing, Deering, Kathleen L., Harshaw, Qing, Leslie, Lori A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239963/
https://www.ncbi.nlm.nih.gov/pubmed/35608754
http://dx.doi.org/10.1007/s12325-021-01991-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239963/
https://www.ncbi.nlm.nih.gov/pubmed/35608754
http://dx.doi.org/10.1007/s12325-021-01991-5

Ejemplares similares